Annex Advisory Services LLC Has $3.47 Million Stake in Amgen Inc. (NASDAQ:AMGN)

Annex Advisory Services LLC decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 29.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,145 shares of the medical research company’s stock after selling 4,623 shares during the quarter. Annex Advisory Services LLC’s holdings in Amgen were worth $3,472,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of AMGN. Centricity Wealth Management LLC acquired a new stake in shares of Amgen during the 4th quarter valued at $25,000. Pinney & Scofield Inc. acquired a new stake in shares of Amgen during the 4th quarter valued at $26,000. Ritter Daniher Financial Advisory LLC DE boosted its holdings in shares of Amgen by 66.2% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 51 shares in the last quarter. Synergy Investment Management LLC acquired a new stake in shares of Amgen during the 4th quarter valued at $34,000. Finally, Atala Financial Inc acquired a new stake in shares of Amgen during the 4th quarter valued at $34,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Down 0.9%

Shares of NASDAQ:AMGN opened at $287.01 on Thursday. The stock has a market cap of $154.33 billion, a price-to-earnings ratio of 38.01, a PEG ratio of 2.63 and a beta of 0.51. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The business’s 50 day moving average is $282.39 and its 200 day moving average is $285.31.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The company had revenue of $8.15 billion for the quarter, compared to analysts’ expectations of $8.05 billion. During the same quarter in the previous year, the firm earned $3.96 earnings per share. Amgen’s quarterly revenue was up 9.4% on a year-over-year basis. On average, sell-side analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Cantor Fitzgerald assumed coverage on Amgen in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $305.00 price objective for the company. Morgan Stanley restated an “equal weight” rating on shares of Amgen in a research report on Friday, May 2nd. Wall Street Zen upgraded Amgen from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 18th. UBS Group restated a “neutral” rating and set a $315.00 price objective (down from $319.00) on shares of Amgen in a research report on Friday, May 2nd. Finally, Piper Sandler lowered their price objective on Amgen from $329.00 to $328.00 and set an “overweight” rating for the company in a research report on Friday, May 16th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $309.22.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.